标准与规范丨病原体核酸快速检测临床实验室规范化应用专家共识

参考文献：

[1]北京医学会检验医学分会. 重症社区获得性肺炎病原微生物实验室诊断专家共识[J]. 中华医学杂志, 2020,100(19):1459-1464. DOI: 10.3760/cma.j.cn112137-20191108-02425 .

[2]中国初级卫生保健基金会病原检测专业委员会,中国医疗保健国际交流促进会分子诊断学分会,中国研究型医院学会神经科学专委会脑炎协作组. 病毒性脑(膜)炎病原体诊断技术应用专家共识[J]. 中华医学杂志, 2023,103(9):648-657. DOI: 10.3760/cma.j.cn112137-20221014-02154 .

[3]Liu W , Lee LP . Toward rapid and accurate molecular diagnostics at home[J]. Adv Mater, 2023,35(21):e2206525. DOI: 10.1002/adma.202206525 .

[4]Candel FJ , Salavert M , Cantón R ,et al. The role of rapid multiplex molecular syndromic panels in the clinical management of infections in critically ill patients: an experts-opinion document[J]. Crit Care, 2024,28(1). DOI: 10.1186/s13054-024-05224-3 .

[5]Virk A , Strasburg AP , Kies KD ,et al. Rapid multiplex PCR panel for pneumonia in hospitalised patients with suspected pneumonia in the USA: a single-centre, open-label, pragmatic, randomised controlled trial[J]. Lancet Microbe, 2024,5(12):100928. DOI: 10.1016/S2666-5247(24)00170-8 .

[6]Olie SE , Andersen CO , van de Beek D ,et al. Molecular diagnostics in cerebrospinal fluid for the diagnosis of central nervous system infections[J]. Clin Microbiol Rev, 2024,37(4):1-6.

[7]Javitt GH , Vollebregt ER . Regulation of molecular diagnostics[J]. Annu Rev Genomics Hum Genet, 2022,23:653-673. DOI: 10.1146/annurev-genom-121521-010416 .

[8]中华人民共和国卫生部办公厅. 医疗机构临床基因扩增检验实验室管理办法(卫办医政发〔2010〕194号)[EB/OL].[ 2025-01-05]. https://www.nccl.org.cn/showRuleDetail?code=07 & id=15 .

[9]中华人民共和国国务院. 病原微生物实验室生物安全管理条例(国务院424号令)[EB/OL]. [ 2025-01-05]. https://www.gov.cn/gongbao/content/2019/content_5468882.htm.

[10]中华人民共和国国务院. 国务院关于修改和废止部分行政法规的决定(国令第797号)[EB/OL]. [ 2025-01-05]. https://www.gov.cn/zhengce/zhengceku/202412/content_6992433.htm.

[11]FDA. Respiratory viral panel multiplex nucleic acid assay - class II special controls guidance for industry and FDA staff[EB/OL]. [ 2025-01-05]. https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/respiratory-viral-panel-multiplex-nucleic-acid-assay-class-ii-special-controls-guidance-industry-and.

[12]FDA. Device to detect and identify nucleic acid targets in respiratory specimens from microbial agents that cause the SARS-Cov-2 respiratory infection and other microbial agents when in a multi-target test[EB/OL]. [ 2025-1-5]. https://www.accessdata.fda.gov/cdrh_docs/reviews/K231481.pdf.

[13]国家卫生健康委. 临床实验室生物安全指南[EB/OL]. [ 2025-01-05]. http://www.nhc.gov.cn/wjw/s9492/202404/e221e9de041041e299299e5e9798a6c0/files/249e7c826f49498087e21e5664d8e591.pdf.

[14]World Health Organization. Laboratory biosafety guidance related to SARS-CoV-2 (COVID-19): interim guidance[EB/OL].[ 2025-1-5]. https://iris.who.int/bitstream/handle/10665/376231/WHO-WHE-EPP-2024.3-eng.pdf?sequence=1.

[15]中国医学装备协会基因检测分会,中国医学装备协会现场快速检测(POCT)装备技术分会,国家医学检验临床医学研究中心,等. 新型冠状病毒核酸快速检测临床规范化应用专家共识[J]. 中华检验医学杂志, 2021,44(8):698-702. DOI: 10.3760/cma.j.cn114452-20210425-00266 .

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。